SCHEMBL3008933

SCHEMBL3008933

Cc1cc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
KMT2A Q03164 3/20 0.44
TSHR P16473 1/20 0.42
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 2/20 0.40
TP53 P04637 2/20 0.40
KDM4E B2RXH2 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
CHRM1 P11229 1/20 0.37
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008798 0.93 LMNA (0.47) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL3014938 0.92 CHRM4 (0.43) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3005306 0.90 TSHR (0.43) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL3010503 0.87 ALDH1A1 (0.43) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL3015990 0.87 TSHR (0.42) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL2998544 0.87 TSHR (0.44) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL3014210 0.86 MEN1 (0.45) LMNAKMT2AMAPTSMN1; SMN2ALDH1A1
SCHEMBL3003812 0.86 CTSS (0.41) SMN1; SMN2RAB9A
SCHEMBL3020120 0.86 MAPT (0.42) LMNAKMT2ATSHRMAPTSMN1; SMN2
SCHEMBL3009591 0.86 LPAR1 (0.42) LMNAKMT2AMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885KMT2A 2680/4885TSHR 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.